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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the beneficial and harmful effects of pharmacological treatment for adolescents and adults with borderline personality disorder
(BPD).
B A C K G R O U N D
Description of the condition
Borderline personality disorder (BPD) is a condition first recog-
nised in the 1960s (Gunderson 2009; Kernberg 1967; Kernberg
1975). Historically, the term BPD was coined by Adolph Stern
to describe a condition in the ’borderland’ between psychosis and
neurosis (Stern 1938). Subsequent psychoanalytic contributions
(especially that of Kernberg 1975) have reaffirmed this distinction,
emphasising that the capacity to test reality remains grossly intact
but is subject to subtle distortions, especially under stress.
According to current diagnostic criteria, BPD is characterised by
a pervasive pattern of instability in affect regulation, impulse con-
trol, interpersonal relationships, and self-image (APA 2013;WHO
1993). Clinical hallmarks include emotional dysregulation, im-
pulsive aggression, repeated self-injury, and chronic suicidal ten-
dencies (Fonagy 2009; Lieb 2004). Whereas some authors have
suggested that it is a variant of affective disorders (Akiskal 2004),
others claim that it is only the causes of these diseases that par-
tially overlap (Paris 2007). Despite the classification challenges in
defining and delimiting the condition, BPD is still being widely
researched. Its importance stems from the large amount of suffer-
ing of the persons concerned (Stiglmayr 2005; Zanarini 1998), de-
bilitating functional impairments (Gunderson 2011a; Gunderson
2011b; Niesten 2016; Skodol 2002; Soetmann 2008b), and from
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the significant impact it has on mental health services (Cailhol
2015; Hörz 2010; Soetmann 2008a; Tyrer 2015; Zanarini 2004a;
Zanarini 2012). It is estimated that about 60% to 78% of BPD pa-
tients attempt suicide (Links 2009), though the rate of completed
suicides is far less. Zanarini and colleagues found suicide rates of
4.5%during 16 years of follow-up (Zanarini 2015), whereas Stone
1993 reported a suicide rate of 8.5% after 16.5 years. Study es-
timates of the lifetime risk of suicide among patients with BPD
range from 3% to 10% (Links 2009). Suicidal behaviour is re-
ported to occur in up to 84% of patients with BPD (Goodman
2012; Soloff 2002), and comorbid mood disorders or substance
use disorders are the most common risk factors associated with
successful suicide attempts (Black 2004; Doyle 2016; Yen 2004).
The definition of BPD in the Diagnostic and Statistical Manual
of Mental Disorders (DSM) Fifth Edition (DSM-5; APA 2013),
Fourth Edition Text Revision (DMS-IV-TR; APA 2000) and
Fourth Edition (DSM-IV; APA 1994) comprises nine criteria that
cover the features mentioned above. At least five criteria should
be met for a definite categorical BPD diagnosis to be made, and
four criteria for probable diagnosis (see Appendix 1). In the alter-
native diagnostic classification system of the World Health Orga-
nization (WHO), theInternational Classification of Diseases, which
is currently in its tenth edition (ICD-10; WHO 1993), the relat-
ing condition is referred to as “Emotionally unstable personality
disorder (F60.3)”, of which there is an impulsive type (F60.30)
and a borderline type (F60.31: see Appendix 2). The latter essen-
tially overlaps with the DSM-IV definition. There are 10 possi-
ble criteria defined that very closely reflect the DSM criteria, with
the exception of one criterion which is not included in the DSM
(“4. Difficulty in maintaining any course of action that offers no
immediate reward”; WHO 1993). Out of 10 possible criteria at
least five must be met, one of which must be “a marked tendency
to quarrelsome behaviour and to conflicts with others, especially
when impulsive acts are thwarted or criticised”.
Overall, the prevalence of BPD in the general population is es-
timated to be about 1.5% (Torgersen 2012), with findings of
single epidemiologic studies ranging between 0.6% (Coid 2006)
and 2.7% (Trull 2010). In clinical populations BDP occurs fre-
quently (Munk-Jørgensen 2010), with studies reporting a preva-
lence ranging from 9.3% to 46.3% and a mean point prevalence
across studies of 28.5% (Torgersen 2012). Though BPD is pre-
dominantly diagnosed in women (75%; APA 2000), it is esti-
mated to be equally frequent in men (Lenzenweger 2007; Ten
Have 2016; Torgersen 2001; Torgersen 2012). BPD commonly
co-occurs with mood disorders, substance misuse, eating disor-
ders, post-traumatic stress disorder (PTSD), attention-deficit hy-
peractivity disorder (ADHD), and is also associated with other
personality disorders (Coid 2006; Lenzenweger 2007; Stepp2012;
Storebø 2014; Tomko 2014).
Although the short- to medium-term outcome of BPD is poor,
there is some evidence that long-term follow-ups show a more
favourable course, with remission rates of about 85% to 88%
within 10 years (Gunderson 2011b; Zanarini 2007). Here, how-
ever, remission only means that diagnostic criteria are not ful-
filled and does not indicate the absence of any symptoms. Indeed,
whereas acute symptoms - such as self-mutilation, help-seeking
suicide threats or attempts and impulsivity - in most cases de-
crease with time, affective symptoms reflecting areas of chronic
dysphoria, such as chronic feelings of emptiness, intense anger or
profound abandonment, largely remain (Zanarini 2007). There-
fore the majority of people with BPD still have significant levels
of symptoms and experience severe and persistent impairment in
social functioning (Kongerslev 2015; Ng 2016). Risk factors for a
poorer long-term outcome are comorbid substance use disorders,
PTSD, and anxiety cluster disorders (Zanarini 2005; Zanarini
2007), and also a family history of psychiatric disorder (especially
mood disorders and substance use disorders), as well as demo-
graphic issues such as older age, longer treatment history, patho-
logical childhood experiences, temperament issues, and adult psy-
chosocial functioning (Chanen 2012; De Fruyt 2014; Kongerslev
2015; Zanarini 2007).
People with BPDhave difficulties achieving andmaintaining voca-
tional and social functioning over time (Zanarini 2010). Further-
more treatment-seeking people with personality disorders, such as
BPD, pose a high economic burden on society (van Asselt 2007).
Effective treatments could potentially decrease the high costs as-
sociated with the condition (Soetmann 2008a). The problem of
deliberate self-harm is also a particular issue within this group
(Ayodeji 2015; Kongerslev 2015; Linehan 1997; Rossouw 2012).
Inmedical settings, peoplewithBPDoftenpresent after self-harm-
ing behaviour or in suicidal crisis and are treated in emergency set-
tings, often involving repeated psychiatric hospitalisations (Bender
2006; Cailhol 2015).
In summary, BPD is a condition that has been extensively stud-
ied. It has a major impact on health facilities, as those affected
often present in crisis. The recovery from symptoms or func-
tional impairment (or both) was previously considered likely for
only a low percentage of people diagnosed with BPD. However,
the long-term course is better than what was previously assumed,
due to more favourable symptomatic recoveries (Zanarini 2012).
Nonetheless, people with BPD continue to have considerable in-
terpersonal and functional problems, and sustainable recovery ap-
pears difficult to attain (Biskin 2015; Kongerslev 2015; Rossouw
2012).
Description of the intervention
To date, all major treatment guidelines consider psychotherapy
as the treatment of choice for BPD and assign drugs an adjunc-
tive role (e.g. APA 2001; DGPPN 2009; Herpertz 2007; National
Health and Medical Research Council 2013; NICE 2009). How-
ever, the large majority of people with BPD are prescribed psy-
chotropic medications during the course of their illness. This may
be the case in times of crisis, when people with BPD present to
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mental health services with raised suicidality or parasuicidality, im-
pulsivity-associated outbreaks, psychotic-like exacerbations, severe
dissociations or aggravations of comorbid conditions (e.g. mood
disorders), and when medications are used to achieve short-term
stabilisation. Such crisis interventions will not be considered here
but are subject to another Cochrane Review, which is currently
being updated (Borschmann 2012).
In contrast to short-term crisis medication, up to 84.1% of peo-
ple with BPD have been reported to use standing psychotropic
medications (Bender 2001; Zanarini 2015), and as many as 92%
have been reported to use any psychotropic medication for a non-
specified period of time (Paton 2015). Indeed, it is a common
finding that people with BPD are more likely to use psychotropic
medications than people with other psychiatric conditions such
as major depressive disorder (Bender 2001; Bender 2006), mood
or anxiety disorders in general (Ansell 2007), or other personality
disorders (Zanarini 2004a).
Studies across different countries show that antidepressants are
the class of medication most often prescribed to BPD pa-
tients (Bender 2001; Knappich 2014; Makela 2006; Paton 2015;
Sansone 2003; Zanarini 2015). Zanarini and colleagues found
that 79.7% were taking antidepressant medication, followed by
anxiolytics (46.6%), neuroleptics (38.6%), and mood stabilisers
(35.9%) (Zanarini 2015). They also found that about 71% of
people with BPD were using standing medications at six-year fol-
low-up (Zanarini 2004a; Zanarini 2004b), and that they were still
more likely to be using antidepressants, mood stabilisers, antipsy-
chotics or anxiolytics than axis-II comparison participants at 16-
year follow-up (Zanarini 2015). Polypharmacy is common, with
reports of people with BPD taking, on average, 2.02 psychotropic
medications at a time (Ansell 2007), and up to 28.6% taking four
or more medications (Zanarini 2004a; Zanarini 2004b).
In summary, most BPD patients are taking psychotropic drugs for
sustained periods of time, though medication is only regarded as
an adjunctive to psychotherapy. Different classes of medication
are used, with antidepressants being used most frequently, but
there is no standard treatment. To date, any drug use in BPD
is off-label (if not targeted at associated psychopathology such as
depression or anxiety), but up to 82% of BPD patients without
comorbid conditions receive pharmacotherapy to directly target
BPD symptoms (Paton 2015).
How the intervention might work
To date, there is broad consensus about no single drug being able
to substantially ’treat’ BPD itself (e.g. APA 2001; Biskin 2012;
National Health and Medical Research Council 2013).
In fact, drug treatment options are chosen with the intent to ame-
liorate distinct symptoms or symptom clusters (also called ’symp-
tom domains’) that a certain person with BPD may experience.
These may either be symptoms specific to BPD (i.e. as defined in
the diagnostic criteria) or BPD-unspecific ones, such as depression
or anxiety, which are also common in BPD. A drug is mostly cho-
sen due to its known efficacy in treating similar symptoms in other
conditions (e.g. depression), or in conditions with putative similar
underlying neurobiological features (e.g. impulsivity-related dis-
orders). As a consequence, many different classes of drugs are used
in BPD, depending on the individual clinical picture a person with
BPDmay experience (Bender 2001; National Health andMedical
Research Council 2013; Zanarini 2015). As part of an integrated
treatment plan, drug treatment may also be given with the intent
to facilitate behaviourally-mediated learning processes as activated
in a concurrent psychotherapy.
The rationale for using selective serotonin reuptake inhibitors in
the treatment of BPD is that the serotonergic system has repeat-
edly been shown to be associated with low prefrontal serotonergic
transmission in BPD (Herpertz 2007). The putative actions of
atypical neuroleptics are also thought to impact the serotonergic
system through a high 5HT1a receptor affinity and 5HT2a recep-
tor antagonism. Therefore, atypical antipsychotics can be expected
to have a stabilising effect on mood and anxiety, but also impulsiv-
ity and aggression (Herpertz 2007). Mood stabilisers are also used
due to their stabilising effects on affective symptoms (Herpertz
2007). In recent years, omega-3 fatty acids (polyunsaturated fatty
acids; PUFAs) have come into the focus of attention, as PUFAs de-
ficiencies have been identified in many mental illnesses, and they
have been assigned a role in impulsivity, mood and even suicidality
(Gören 2011; Pompili 2017). Sedatives, such as benzodiazepines,
are also commonly used in clinical practice with the intent to
improve sleep, or decrease anxiety or agitation (Martinho 2014).
However, the use of such agents is critical, due to their self-harming
and addictive potential and also due to their well-known and un-
favourable impact on learning processes as, for example, intended
by psychotherapy (Hunter 2000; Westra 2002). And finally, the
neuropeptide oxytocin has received attention in recent years, be-
cause oxytocin is supposed to lead to better emotion recognition
and more trust in other people (Bakermans-Kranenburg 2013). It
may, therefore, help people with BPD overcome hypersensitivity
to perceived social threat (Meyer-Lindenberg 2011).
Why it is important to do this review
BPD poses a major burden, both personal (Soetmann 2008b) and
financial (Soetmann 2008a), on those directly affected and their
relatives. In 2008, theUSHouse of Representatives passed aHouse
Resolution naming the month of May BPD Awareness Month (
110th Congress 2007 to 2008). This underlines the large public
health problem of BPD. Despite its frequent use in clinical prac-
tice, and research activities on this topic in the last three decades,
any medication in BPD is off-label. All themore, patients and car-
ers must be able to make informed decisions on the basis of the up-
to-date evidence (Ingenhoven 2015; Paris 2015; Silk 2015). This
Cochrane Review aims to systematically identify, investigate, and
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integrate the current state of high-quality evidence on the topic of
pharmacotherapy in BPD.
This is a new protocol for a new review, which will update and
replace the Cochrane Review first published in 2010 (Stoffers
2010). As no published protocol seems to exist, we considered
it necessary to write and publish a protocol before conducting
this review. The Stoffers 2010 review came to the conclusion that
the then available evidence indicated beneficial effects for some
drugs (i.e. second-generation antipsychotics, mood stabilisers and
omega-3 fatty acids), but that the overall quality of the evidence
was not robust enough to draw any reliable conclusions. In the
meantime research has continued in the field, and new findings
may change findings of the previous review. Therefore an update
of this review seems both appropriate and timely (Garner 2016).
O B J E C T I V E S
To assess the beneficial and harmful effects of pharmacological
treatment for adolescents and adults with borderline personality
disorder (BPD).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Patients of all ages, in any setting, with a formal diagnosis of BPD
according to theDiagnostic and Statistical Manual of Mental Disor-
ders (DSM) Third Edition (DSM-III; APA 1980), Third Edition
Revised (DSM-III R; APA 1987), Fourth Edition (DSM-IV; APA
1994), Fourth Edition Text Revision (DSM-IV-TR; APA 2000),
and Fifth Edition (DSM-5; APA 2013)), with or without comor-
bid conditions.
We will require at least 70% of study participants to have a formal
diagnosis of BPD. We will also include studies involving subsam-
ples of BPD patients providing data on these patients are available
separately. We will not include studies that focus on people with
mental impairment, organic brain disorder, dementia, or other se-
vere neurologic diseases, should there be any.
Types of interventions
Any drug or defined combination of drugs administered at any
dosage, prescribed to treat the disorder or its symptoms, compared
to a placebo or active comparator drug(s). We will include studies
that pair drugs with an adjunctive intervention (e.g. psychological
therapies), providing this is given to participants in both the inter-
vention and control arm, and the pharmacological intervention is
unique to the treatment group.
A drug must have been prescribed continuously for a minimum
duration of two weeks for the study to be eligible for our review. In
addition, we will judge the actual duration required for inclusion
in light of the specific mode of action of the drug. Medication
must have been used to treat the disorder or symptoms thereof.
Types of outcome measures
Outcomes can either be self-rated by patients or observer-rated
by clinicians. We will include only adequately validated measures
(plus spontaneous reporting of adverse events).
Primary outcomes
1. BPD severity, as assessed by, for example, the Zanarini
Rating Scale for Borderline Personality Disorder (Zan-BPD;
Zanarini 2003), the Borderline Personality Disorder Severity
Index (BPDSI-IV; Arntz 2003), or the Clinical Global
Impression Scale for Borderline Personality Disorder Patients
(CGI-BPD; Perez 2007).
2. Self-harm, in terms of the proportion of participants with
self-harming behaviour, or as assessed by, for example, the
Deliberate Self-harm Inventory (DSHI; Gratz 2001) or the Self-
harm Behavior Questionnaire (SHBQ; Guttierez 2001).
3. Suicide-related outcomes, as assessed by, for example, the
Suicidal Behaviours Questionnaire (SBQ; Osman 2001) or the
Beck Scale for Suicidal Ideation (BSSI; Beck 1979) or in terms of
the proportion of patients with suicidal acts.
4. Functioning, as assessed by, for example, the Global
Assessment Scale (GAS; Endicott 1976), the Global Assessment
of Functioning Scale (GAF; APA 1987) or the Social
Functioning Questionnaire (SFQ; Tyrer 2005).
Secondary outcomes
1. Anger, as assessed by, for example, the “Hostility” subscale
of the Symptom Checklist-90-Revised (SCL-90-R; Derogatis
1994), or the State-Trait Anger Expression Inventory (STAXI;
Spielberger 1988).
2. Affective instability, as assessed by, for example, the relevant
item or subscale on the Zan-BPD (Zanarini 2003), CGI-BPD
(Perez 2007) or BPDSI-IV (Arntz 2003).
3. Chronic feelings of emptiness, as assessed by, for example,
the relevant item or subscale on the Zan-BPD (Zanarini 2003),
CGI-BPD (Perez 2007) or BPDSI-IV (Arntz 2003).
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4. Impulsivity, as assessed by, for example, the Barrett
Impulsiveness Scale (BIS; Barrett 1995), or the Anger, Irritability
and Assault Questionnaire (AIAQ; Coccaro 1991).
5. Interpersonal problems, as assessed by, for example, the
Inventory of Interpersonal Problems (IIP; Horowitz 1988), or
the relevant item or subscale of the Zan-BPD (Zanarini 2003),
CGI-BPD (Perez 2007) or BPDSI-IV (Arntz 2003), or SCL-90-
R (Derogatis 1994).
6. Abandonment, as assessed by, for example, the relevant
item or subscale on the Zan-BPD (Zanarini 2003), CGI-BPD
(Perez 2007) or BPDSI-IV (Arntz 2003).
7. Identity disturbance, as assessed by, for example, the
relevant item or subscale on the Zan-BPD (Zanarini 2003),
CGI-BPD (Perez 2007) or BPDSI-IV (Arntz 2003).
8. Dissociation and psychotic-like symptoms, as assessed by,
for example, the Dissociative Experience Scale (DES; Bernstein
1986), or the Brief Psychiatric Rating Scale (BPRS; Overall
1962).
9. Depression, as assessed by, for example, the Beck
Depression Inventory (BDI; Beck 1961), or the Montgomery
Åsberg Depression Rating Scale (MADRS; Montgomery 1979).
10. Attrition, in terms of patients lost after randomisation in
each group.
11. Adverse effects, as measured by use of standardised
psychometric rating scales such as the Systematic Assessment for
Treatment Emergent Events (SAFTEE; Levine 1986), laboratory
values or spontaneous reporting.
Search methods for identification of studies
Electronic searches
We will search the electronic databases and trials registers listed
below to identify relevant trials.
1. Cochrane Central Register of Controlled Trials
(CENTRAL; current issue), in the Cochrane Library, which
includes the Cochrane Developmental, Psychosocial and
Learning Problems Specialised Register
2. MEDLINE Ovid (1948 onwards)
3. Embase Ovid (1980 onwards)
4. CINAHL EBSCOhost (Cumulative Index to Nursing and
Allied Health Literature; 1980 onwards)
5. PsycINFO Ovid (1806 onwards)
6. ERIC EBSCOhost (Education Resources Information
Center; 1966 onwards)
7. BIOSIS Previews Web of Science Clarivate Analytics (1969
onwards)
8. Web of Science Core Collection Clarivate Analytics (1900
onwards)
9. Sociological Abstracts ProQuest (1952 onwards)
10. LILACS (Latin American and Caribbean Health Science
Information database; all available years; lilacs.bvsalud.org/en)
11. OpenGrey (www.opengrey.eu)
12. Copac National, Academic and Specialist Library
Catalogue (COPAC; copac.jisc.ac.uk)
13. ProQuest Dissertations and Theses A&I (1973 onwards)
14. DART Europe E-Theses Portal (www.dart-europe.eu/basic-
search.php)
15. Networked Digital Library of Theses and Dissertations
(NDLTD; www.ndltd.org)
16. Australian New Zealand Clinical Trials Registry
(ANZCTR; www.anzctr.org.au/BasicSearch.aspx)
17. ClinicalTrials.gov (clinicaltrials.gov)
18. EU Clinical Trials Register (www.clinicaltrialsregister.eu/
ctr-search/search)
19. ISRCTN Registry (www.isrctn.com)
20. UK Clinical Trials Gateway (www.ukctg.nihr.ac.uk/
#popoverSearchDivId)
21. WHO International Clinical Trials Registry Platform
(ICTRP; who.int/ictrp/en)
The search strategy for MEDLINE is in Appendix 1 and we will
modify it for other databases using the appropriate syntax and
controlled terms. We will not limit our searches by language, year
of publication, or type of publication. We will seek translation of
the relevant sections of non-English language articles.
Searching other resources
We will handsearch relevant journals including the Journal of Per-
sonalityDisorders; the American Journal of Psychiatry; JAMAPsy-
chiatry; British Journal of Psychiatry; ACTA Psychiatrica Scan-
dinavica; Journal of the American Academy of Child and Ado-
lescent Psychiatry; Personality Disorders: Theory, Research and
Treatment; and the Journal of Clinical Psychiatry. Additionally,
we will contact researchers working in the field by email, to ask
for unpublished data. We will also trace cross-references from rel-
evant literature. Finally, we will search for unpublished data on
the websites of the United States Food and Drug Administration
(FDA; www.fda.gov) and the EuropeanMedicines Agency (EMA;
www.ema.europa.eu/ema).
Data collection and analysis
We will conduct this review according to guidelines set out in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011a), and perform the analyses using the latest version of Review
Manager 5 (RevMan 5), Cochrane’s statistical software (Review
Manager 2014).
Selection of studies
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Six review authors (JMSW, OJS, BAV, MLK, JTM, SSN) will
work in three pairs and independently screen titles and abstracts
of all records retrieved by the searches; we will resolve uncertainty
or disagreement by consensus. For records that could be eligible
RCTs, we will obtain the full-text report and assess it for eligibil-
ity based on the inclusion criteria (Criteria for considering studies
for this review). Review authors will discuss disagreements, and if
they cannot reach an agreement they will consult a third review
author (ES or KL). We will list apparently relevant RCTs that do
not fulfil the inclusion criteria with reasons for exclusion in the
’Characteristics of excluded studies’ tables.We will use Covidence
software to keep track of appraised trials and decisions. To ensure
transparency of study selection, we will provide a flow chart in ac-
cordance with the PRISMA statement, to show how many records
have been excluded and for what reason (Moher 1999).
Data extraction and management
All review authors will extract data. Review authors will work in
pairs and will complete the data collection form independently
to ensure accuracy. We will resolve disagreements by discussion
or use an arbiter (ES) if required. JMSW and OJS will enter the
data into RevMan 5 (ReviewManager 2014). In those cases where
there are not enough data or data are unclear in the published
trial reports, we will contact the trial authors, requesting them to
supply the missing information. We will develop data extraction
forms to facilitate standardisation of data extraction.
Assessment of risk of bias in included studies
All review authors will assess the risk of bias using Cochrane’s tool
for assessing risk of bias (Higgins 2017). For each included trial,
data extractorswill independently evaluate each risk of bias domain
- Appendix 4 - as being at low, unclear (uncertain) or high risk
of bias, resolving disagreements by discussion. We will categorise
trials that have a low risk of bias in all domains at low risk of
bias overall, and we will consider trials with one or more unclear
or high risk of bias domains as trials at high risk of bias overall.
Given the risk of overestimation of beneficial intervention effects
and underestimation of harmful intervention effects in RCTs with
unclear or inadequate methodological quality (Kjaergard 2001;
Lundh 2012;Moher 1998; Savovi 2012a; Savovi 2012b; Schulz
1995; Wood 2008), we will assess the influence of risk of bias on
our results (see Sensitivity analysis).
Measures of treatment effect
Dichotomous data
Wewill summarise dichotomous data as risk ratios (RRs)with 95%
confidence intervals (CIs). We will calculate the risk difference
(RD) and the number needed to treat for an additional beneficial
outcome (NNTB) or for an additional harmful outcome (NNTH)
if there is a significant effect of the intervention.
Continuous data
For continuous data, we will compare the mean score between
the two groups to give a mean difference (MD) and present this
with 95% CIs. We will use the overall MD, where possible, to
compare the outcome measures from trials. We will estimate the
standardised MD (SMD) where different outcome measures are
used to measure the same construct in the trials. We will calculate
SMDs using end-scores at post-treatment results and, in a separate
analysis, follow-up data. We will bundle follow-up data in six-
month steps. Where the direction of a scale is opposite to most of
the other scales, we will multiply the corresponding mean values
by −1 to ensure adjusted values. If the trials do not report means
and standard deviations but report other values like t-tests and P
values, we will try to transform these into standard deviations.
Our first choice will be to calculate effect sizes on the basis of
intention-to-treat (ITT) data. If means and standard deviations
from an ITT analysis and missing values that were replaced are
available, we will use these data. In other cases, we will conduct
the analysis using only the available data.
We will perform all calculations using the latest release of RevMan
5 software (Review Manager 2014).
Unit of analysis issues
Repeated observations
We will calculate study estimates on the basis of post-treatment
group results. We will conduct separate analyses for data from dif-
ferent points of measurement (i.e. we will use the last measure-
ment where post-treatment follow-up data at six-month intervals
is available). We will not use interim observations.
Cluster-randomised trials
Where trials have used cluster randomisation, we anticipate that
investigators will have presented their results after appropriately
controlling for clustering effects (robust standard errors or hierar-
chical linear models). If it is unclear whether a cluster-randomised
trial has used appropriate controls for clustering, we will contact
the investigators for further information. Where appropriate con-
trols have not been used, we will request and reanalyse individual
participant data using multilevel models that control for cluster-
ing. If individual participant data are not available, wewill look for
information on intraclass correlation coefficients to adjust for the
potential clustering effects. Following this, we will analyse effect
sizes and standard errors in RevMan 5 (Review Manager 2014),
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using the generic inverse method (Higgins 2011b). If there is in-
sufficient information to control for clustering, we will enter out-
come data into RevMan 5 (Review Manager 2014), using indi-
viduals as the units of analysis, and conduct a sensitivity analysis
to assess the potential biasing effects of inadequately controlled
cluster-randomised trials (Donner 2002); see Sensitivity analysis.
Cross-over trials
We plan to include data from randomised cross-over studies up to
the point of first cross-over (first period only) (Curtin 2002). We
will not consider outcomes from subsequent periods due to the
likelihood of carry-over effects from the preceding treatment(s).
We will not combine repeated observations on participants in one
meta-analysis.
Studies with multiple treatment groups
If a trial compares more than two intervention groups, we will
include all pair-wise comparisons as long as they are not subject
to the same meta-analysis. If a trial includes two arms of different
doses of a certain drug that are tested against placebo, we will com-
bine the experimental groups into a single group, as recommended
in the Cochrane Handbook for Systematic Reviews of Interventions,
making a single, pair-wise comparison (Higgins 2011b). Thus we
will avoid including the same group of participants twice in the
same meta-analysis.
Adjustment for multiplicity
Wewill adjust the P values andCIs formultiplicity due to themany
secondary outcome comparisons following the method described
by Jakobsen 2014b.
Dealing with missing data
We will try to obtain any missing data, including incomplete out-
come data, by contacting trial authors. We will report this infor-
mation in the ’Risk of bias’ tables.
We will evaluate the methods used to handle the missing data in
the publications and to what extent it was likely that the missing
data influenced the results of outcomes of interest. For preference,
we will calculate effect sizes on the basis of ITT data. If only avail-
able data are reported, we will calculate effect sizes on this basis.
Where dichotomous data are not presented on the basis of ITT
data, we will add the number of participants lost in each group to
the participants with unfavourable results, acting on the assump-
tion that most patients with BPD do not get lost at random. For
continuous outcomes, we will discuss each trial’s methodology for
dealing with missing continuous data (e.g. last observation car-
ried forward or modified ITT approach). We will use per protocol
analysis, as available from the trial reports (that is, results are based
on the number of patients at follow-up).
If data are not reported in an immediately usable way, we will
consult a statistician.
We will assess results derived from statistically processed data in
sensitivity analyses. See Sensitivity analysis.
Assessment of heterogeneity
Wewill assess studies for clinical homogeneity with respect to type
of pharmacological interventions, setting and control groups. We
will take into account the number of studies and study character-
istics, such as duration, dose and participants, to judge if hetero-
geneity is more probable due to clinical (i.e. explainable factors)
or to unknown factors. In case of substantial heterogeneity, we
will make up subgroups according to study characteristics, such
as study size, duration, dose or participants, and discuss the most
apparent sources of heterogeneity. We will evaluate methodologi-
cal heterogeneity by comparing the design of trials. See Subgroup
analysis and investigation of heterogeneity.
We will investigate statistical heterogeneity within a certain com-
parison by visual inspection of the graphs and the I² statistic
(Higgins 2003). We will judge I² values between 0% and 40%
to indicate little heterogeneity, between 30% and 60% to indi-
cate moderate heterogeneity, between 50% and 90% to indicate
substantial heterogeneity, and between 75% and 100% to indi-
cate considerable heterogeneity (Deeks 2017). We will also assess
statistical heterogeneity by Chi² test (P < 0.10) and tau² an
estimate of between-study variability.
Assessment of reporting biases
We will provide funnel plots for comparisons with sufficient pri-
mary studies and we will perform Egger’s statistical test for small-
study effects (Egger 1997). We will not use a visual inspection
of the funnel plot if there are fewer than 10 studies in the meta-
analysis, as recommended in theCochrane Handbook for Systematic
Reviews of Interventions (Sterne 2017).
Data synthesis
Wewill perform statistical analyses according to recommendations
in the latest version of the Cochrane Handbook for Systematic Re-
views of Interventions (Deeks 2017). In carrying out themeta-anal-
ysis we will use the inverse-variance method, in order to give more
weight to more precise estimates from studies with less variance
(mostly larger studies). We will divide the doses and the controls
into different comparisons, ensuring that the treatment compar-
isons are comparable and homogeneous. We will use the random-
effects model for meta-analysis, since we expect some degree of
clinical heterogeneity to be present in most cases, though not so
substantial as to prevent pooling in principle. For trials with a
high level of statistical heterogeneity, and where the amount of
clinical heterogeneity makes it inappropriate to use these trials in
7Pharmacological interventions for people with borderline personality disorder (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
meta-analyses, we will provide a narrative description of the trial
results. If we consider data pooling to be feasible, we will pool
the primary studies effects and calculate their 95% CIs. If a trial
provides more than one measure for the same outcome construct
(e.g. several questionnaires for the assessment of depression), we
will select the one used most often in the whole pool of included
studies for effect size calculation, in order to minimise heterogene-
ity of outcomes in form and content. If a study reports data of
two assessment instruments that are equally frequently used, two
review authors will discuss the issue and choose the one which is,
in its content, most appropriate for assessing BPD patients. We
will prefer observer-rated measures as the primary analysis.
Subgroup analysis and investigation of heterogeneity
We will conduct a subgroup analysis to make hypotheses about
the subgroups mentioned below.
1. Age (15 to under 18 years of age, 18 to 50 years of age,
above 50 years of age)
2. Sex (male versus female)
3. Cormorbidity (patients with comorbidity versus patients
without comorbidity)
4. Doses
5. Different setting (outpatient compared to inpatient)
6. Differences between different types of medication within
the same class (for example, antipsychotic, antidepressant)
Heterogeneity-adjusted required information size
and Trial Sequential Analysis
Trial Sequential Analysis (TSA) is a methodology that combines
a required information size (RIS) calculation for a meta-analysis
with the threshold for statistical significance (Brok 2008; Brok
2009; Thorlund 2009; Wetterslev 2008). TSA is a tool for quan-
tifying the statistical reliability of the data in cumulative meta-
analysis, adjusting P values for sparse data and for repetitive testing
on accumulating data (Brok 2008; Brok 2009; Thorlund 2009;
Wetterslev 2008).
Comparable to the a priori sample size estimation in a single ran-
domised trial, a meta-analysis should include a RIS calculation at
least as large as the sample size of an adequately powered single
trial to reduce the risk of random error. TSA calculates the RIS
in a meta-analysis and provides an alpha-spending boundary to
adjust the significance level for sparse data and repetitive testing
on accumulating data (CTU 2011; Wetterslev 2008), and conse-
quently the risk of random error can be assessed. Multiple analysis
of accumulating data when new trials emerge leads to repeated
significant testing and hence introduces multiplicity, thus use of
a conventional P value is prone to exacerbate the risk of random
error (Berkey 1996; Lau 1995). Meta-analyses not reaching the
RIS are analysed with trial sequential alpha-spending monitoring
boundaries analogous to interim monitoring boundaries in a sin-
gle trial (Wetterslev 2008). This approach will be crucial in fu-
ture updates of the review. We will calculate an RIS on all out-
comes in the review. If a TSA does not reveal significant findings
(no crossing of the alpha-spending boundary and no crossing of
the conventional boundary of P = 0.05) before the RIS has been
reached, then the conclusion should either be that more trials are
needed to reject or accept an intervention effect that was used for
calculation of the required sample size or - in the case when the
cumulated Z-curve enters the futility area - the anticipated effect
can be rejected. We will calculate the a priori diversity-adjusted
required information size (that is, number of patients required to
detect or reject a specific intervention effect in the meta-analysis),
and perform a TSA for the primary outcomes based on the fol-
lowing a priori assumptions.
1. The standard deviation of the primary outcome is 1.0.
2. An anticipated intervention effect equal to Hedge’s g of 0.5.
3. A maximum type I error of 5% (alpha).
4. A maximum type II error of 20% (beta; equal to a
minimum 80% power).
5. A priori anticipated 50% diversity (Brok 2008; Brok 2009;
Thorlund 2009; Wetterslev 2008; Wetterslev 2009).
We will also calculate a post hoc, low bias, risk diversity-adjusted
required information size (that is, the number of patients required
to detect or reject a specific intervention effect in the meta-anal-
ysis), and perform a TSA for the primary outcomes based on the
following estimated assumptions.
1. The standard deviation of the primary outcome in patients
in the control group of trials with low risk of bias.
2. The estimated intervention effect in trials with low risk of
bias.
3. A maximum type I error of 5% (alpha).
4. A maximum type II error of 20% (beta; equal to a
minimum 80% power).
5. The estimated diversity in the trials included in the meta-
analysis (Brok 2008; Brok 2009; Thorlund 2009; Wetterslev
2008).
’Summary of findings’ tables
We will used the GRADE approach to construct a ’Summary of
findings’ table in which to document all review outcomes. The
GRADE approach appraises the quality of a body of evidence
based on the extent to which one can be confident that an esti-
mate of effect or association reflects the item being assessed. Con-
siderations are due to: within-trial risk of bias; directness of the
evidence; heterogeneity of the data; precision of effect estimates;
and risk of publication bias (Andrews 2013a; Andrews 2013b;
Balshem 2011; Brunetti 2013; Guyatt 2011a; Guyatt 2011b;
Guyatt 2011c; Guyatt 2011d; Guyatt 2011e; Guyatt 2011f;
Guyatt 2011g; Guyatt 2011h; Guyatt 2013a; Guyatt 2013b;
Guyatt 2013c;Mustafa 2013).When possible, wewill use theMD
or the RR, and we will use Trial Sequential Analysis (TSA) to rate
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the imprecision (Jakobsen 2014a).We will report the four primary
outcomes (BPD severity, self-harm, suicide-related outcomes, and
mental health status) and the three secondary outcomes (interper-
sonal problems, attrition, and adverse events) in the ’Summary of
findings’ table for the main comparison (Atkins 2004).
Sensitivity analysis
We will assess the impact of heterogeneity on the overall pooled
effect estimate by removing studies (’outliers’) that are contribut-
ing to the heterogeneity. We will remove outliers one by one and
assess the impact on the overall outcome.
Wewill conduct sensitivity analyses to determine whether findings
are sensitive to the following.
1. Decisions made during the review process (such as our
assessment of the level of clinical heterogeneity).
2. Impact of bias (studies with low and high risk of bias).
3. Type of model used for analysis (repeating the analysis
using the fixed-effect model to test the robustness of the results).
4. Type of data collection (for example, different ways to
measure adverse events).
5. Imputed data (comparing the analyses with available
outcome data with those using the intention-to-treat (ITT)
approach).
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A P P E N D I C E S
Appendix 1. DSM diagnostic criteria for BPD (301.83)
DSMThird Edition (DSM-III; APA 1980)
301.83 BPD
DSMFourthEditionTextRevision (DSM-
IV-TR; APA 2000)
301.83 BPD
DSM Fifth Edition (DSM-5; APA 2013)
301.83 BPD
Diagnostic criterion A
5 of the following are required
1. Impulsivity or unpredictability in at least
2 areas that are potentially self-damaging (e.
Diagnostic criterion A
A pervasive pattern of instability of inter-
personal relationships, self-image, and af-
fects, andmarked impulsivity beginning by
Diagnostic criterion A
A pervasive pattern of instability of inter-
personal relationships, self-image, and af-
fects, and marked impulsivity, beginning
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(Continued)
g. spending, sex, substance use, shoplifting,
overeating, physically self-damaging acts)
2. A pattern of unstable and intense inter-
personal relationships (e.g. marked shifts of
attitude, idealization, devaluation, manip-
ulation (consistently using others for one’s
own ends))
3. Inappropriate, intense anger or lack of
control of anger (e.g. frequent displays of
temper, constant anger)
4. Identity disturbance manifested by un-
certainty about several issues relating to
identity, such as self-image, gender identity,
long-term goals or career choice, friendship
patters, values, and loyalties (e.g. ’Who am
I’, ’I feel like I am my sister when I am
good’)
5. Affective instability: marked shifts from
normal mood to depression, irritability, or
anxiety, usually lasting a fewhours and only
rarely more than a few days, with a return
to normal mood
6. Intolerance of being alone (e.g. frantic ef-
forts to avoid being alone, depressed when
alone)
7. Physically self-damaging acts (e.g. suici-
dal gestures, self-mutilation, recurrent ac-
cidents or physical fights)
8. Chronic feelings of emptiness or bore-
dom
early adulthood and present in a variety of
contexts, as indicated by 5 (or more) of the
following
1. Frantic efforts to avoid real or imagined
abandonment (note: do not include suici-
dal or self-mutilating behavior covered in
criterion 5)
2. A pattern of unstable and intense inter-
personal relationships characterized by al-
ternating between extremes of idealization
and devaluation
3. Identity disturbance: markedly and per-
sistently unstable self-image or sense of self
4. Impulsivity in at least 2 areas that are po-
tentially self-damaging (e.g. spending, sex,
substance abuse, reckless driving, binge eat-
ing) (note: do not include suicidal or self-
mutilating behavior covered in criterion 5)
5. Recurrent suicidal behavior, gestures, or
threats, or self-mutilating behavior
6. Affective instability due to a marked re-
activity of mood (e.g. intense episodic dys-
phoria, instability, or anxiety usually last-
ing a few hours and only rarely more than
a few days)
7. Chronic feelings of emptiness
8. Inappropriate, intense anger or difficulty
controlling anger (e.g. frequent displays of
temper, constant anger, recurrent physical
fights)
9. Transient, stress-related paranoid
ideation or severe dissociate symptoms
by early adulthood and present in a variety
of contexts, as indicated by 5 (or more) of
the following
1. Frantic efforts to avoid real or imagined
abandonment (note: do not include suici-
dal or self-mutilating behavior covered in
criterion 5)
2. A pattern of unstable and intense inter-
personal relationships characterized by al-
ternating between extremes of idealization
and devaluation
3. Identity disturbance: markedly and per-
sistently unstable self-image or sense of self
4. Impulsivity in at least 2 areas that are po-
tentially self-damaging (e.g. spending, sex,
substance abuse, reckless driving, binge eat-
ing) (note: do not include suicidal or self-
mutilating behavior covered in criterion 5)
5. Recurrent suicidal behavior, gestures or
threats, or self-mutilating behavior
6. Affective instability due to a marked re-
activity of mood (e.g. intense episodic dys-
phoria, irritability, or anxiety ofmood) usu-
ally lasting a fewhours and only rarelymore
than a few days
7. Chronic feelings of emptiness
8. Inappropriate, intense anger or difficulty
controlling anger (e.g. frequent displays of
temper, constant anger, recurrent physical
fights)
9. Transient, stress-related paranoid
ideation or severe dissociative symptoms
Diagnostic criterion B
If under 18, does not meet the criteria for
Identity Disorder
BPD: Borderline personality disorder; DSM: Diagnostic and Statistical Manual of Mental Disorders
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Appendix 2. ICD-10 research criteria for emotionally unstable personality disorder (F60.3)
F 60.30: ICD-10 Emotionally unstable personality disorder,
impulsive type
F 60.31: Emotionally unstable personality disorder, border-
line type
Diagnostic criterion A
The general criteria of personality disorder (F60) must be met
Diagnostic criterion A
The general criteria of personality disorder (F60) must be met
Diagnostic criterion B
At least 3 of the following must be present, 1 of which is 2
1. Marked tendency to act unexpectedly and without considera-
tion of the consequences
2. Marked tendency to quarrelsome behaviour and to conflicts
with others, especially when impulsive acts are thwarted or criti-
cized
3. Liability of outbursts of anger or violence, with inability to
control the resulting behavioural explosions
4. Difficulty in maintaining any course of action that offers no
immediate reward
5. Unstable and capricious mood
Diagnostic criterion B
At least 3 of the symptoms mentioned in criterion B (F60.30)
must be present, and in addition at least 2 of the following
6. Disturbances in and uncertainty about self-image, aims and
internal preferences (including sexual)
7. Liability to become involved in intense and unstable relation-
ships, often leading to emotional crises
8. Excessive efforts to avoid abandonment
9. Recurrent threats or acts of self-harm
10. Chronic feelings of emptiness
ICD-10: International Classification of Diseases - Tenth Edition
Appendix 3. Medline search strategy
1 Borderline Personality Disorder/
2 ((borderline or border-line) adj3 (state* or personalit*)).kf,tw.
3 (“Axis II” or “Cluster B” or flamboyant or “F60.3” or “F60.30” or “F60.31”).kf,tw.
4 (idealization adj5 devaluation).kf,tw.
5 ((vulnerable or hyperbolic) adj3 temperament).kf,tw.
6 (((unstab* or instab* or poor or disturb* or fail* or weak or dysregulat*) adj3 (self* or impuls* or interperson* or identit* or relationship*
or emotion* or affect*)) and (personality or character or PD)).kf,tw.
7 (impulsiv* adj5 (behavio?r or character or personalit*)).kf,tw.
8 (self adj3 (injur* or damag* or destruct* or harm* or hurt* or mutilat*)).kf,tw.
9 (suicidal adj3 behavio?r).kf,tw.
10 (feel* adj3 (empt* or bored*)).kf,tw.
11 (anger adj5 control*).kf,tw.
12 (risk-taking adj3 behavio?r).kf,tw.
13 or/1-12
14 randomized controlled trial.pt.
15 controlled clinical trial.pt.
16 randomi#ed.ab.
17 placebo.ab.
18 randomly.ab.
19 trial.ab.
20 groups.ab.
21 drug therapy.fs.
22 or/14-21
23 exp Animals/ not Humans/
24 22 not 23
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25 13 and 24
Appendix 4. ’Risk of bias’ domains and criteria for assigning judgements
Selection bias
Random sequence generation
1. Low risk of bias. The method used was adequate (e.g. computer-generated random numbers, table of random numbers) or was
unlikely to introduce selection bias.
2. Unclear risk of bias. Information was insufficient for assessment of whether the method used could introduce selection bias.
3. High risk of bias. The method used was likely to introduce bias.
Allocation concealment
1. Low risk of bias. The method used (e.g. central allocation) was unlikely to bias allocation to groups.
2. Unclear risk of bias. Information was insufficient for assessment of whether the method used could bias allocation to groups.
3. High risk of bias. The method used (e.g. open random allocation schedule) could bias allocation to groups.
Performance bias (blinding of participants and personnel)
1. Low risk of bias. The method of blinding was described sufficiently and blinding was conducted in a satisfactory way.
2. Unclear risk of bias. Information was insufficient for assessment of whether adequate blinding was used and whether it was
likely to introduce bias on the estimate of effect.
3. High risk of bias. No blinding or incomplete blinding.
Detection bias (blinding of outcome assessment)
1. Low risk of bias. The method of blinding was described and blinding was conducted in a satisfactory way.
2. Unclear risk of bias. Information was insufficient for assessment of whether the type of blinding used was likely to bias the
estimate of effect.
3. High risk of bias. No blinding or incomplete blinding.
Attrition bias (incomplete outcome data)
1. Low risk of bias. Underlying reasons for missing data probably would not affect outcome measurement regarding effects of
methylphenidate, as all missing data can be considered as missing at random or all data were reported.
2. Unclear risk of bias. Information was insufficient for assessment of whether missing data or the method used to handle missing
data was likely to bias the estimate of effect.
3. High risk of bias. The crude estimate of effects could be biased given the reasons for the missing data, or the methods used to
handle missing data are unsatisfactory.
Reporting bias (selective reporting)
1. Low risk of bias. The trial protocol was available and all prespecified outcomes of interest were reported.
2. Unclear risk of bias. Information was insufficient for assessment of whether selective outcome reporting could have occurred.
3. High risk of bias. Not all of the primary outcomes specified beforehand were reported or participants were excluded after
randomisation.
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Other potential sources of bias
Vested interest
1. Low risk of bias. The trial was not funded by any parties that might be considered to have a conflict of interest (e.g. a
manufacturer of methylphenidate).
2. Unclear risk of bias. The source of funding was not clear.
3. High risk of bias. The trial was funded by parties that might have had a conflict of interest (e.g. a manufacturer of
methylphenidate) or potential conflicts of interest were reported by trial authors.
Other sources of bias
1. Low risk of bias. The trial appeared to be free of other sources of bias.
2. Unclear risk of bias. Information was inadequate for assessment of other possible sources of bias.
3. High risk of bias. Other sources of bias were identified.
Seven of the above domains are specified in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2017). We added
an eighth domain - vested interest. Andreas Lundh and colleagues illustrate the many subtle mechanisms through which sponsorship
and conflict of interest may influence intervention effects on outcomes. For more information, please see editorials by Bero 2013 and
Sterne 2013, and the commentary by Gøtzsche 2015.
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